Evidence map›Paper›PMID 42649897›Full record

ReviewCancers2026

Prognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis.

Michał Kapałka, Estera Pazek, Michał Krawiec, Michał Sikorski, Grzegorz Hirnle, Tomasz Hrapkowicz

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michał KapałkaStudents' Scientific Club at the Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland.ORCID 0000-0002-3293-9923
Estera PazekStudents' Scientific Club at the Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland.ORCID 0009-0003-7570-1530
Michał KrawiecStudents' Scientific Club at the Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland.
Michał SikorskiStudents' Scientific Club at the Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland.
Grzegorz HirnleDepartment of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland.
Tomasz HrapkowiczDepartment of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland.ORCID 0000-0002-8945-7351

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary pericardial mesothelioma (PPM) is a rare and aggressive tumor. We aimed to analyze diagnostic pathways and factors influencing survival.

methodsA systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD420261277326). MEDLINE, Web of Science, and EMBASE were searched up to March 2025. Case reports and case series published from 2010 onwards de- scribing histologically confirmed PPM were included. Data were extracted independently by multiple reviewers. Risk of bias was assessed using Joanna Briggs Institute tools. Individual patient data were pooled. Survival was analyzed using Kaplan-Meier and log-rank tests, and factors associated with survival ≥12 months were evaluated using univariable logistic regression.

resultsA total of 120 patients were included (108 case reports, 4 case series). Diffuse pericardial involvement predominated (74.2%), while localized tumors occurred in 30.8%. Constrictive pericarditis was present in 31.7%. Median overall survival from diagnosis was 7.4 months (IQR 1.75-13.5). Use of CT and PET in the diagnostic process was associated with longer survival (CT: 9.1 vs. 1.5 months,

conclusionsPPM carries a poor prognosis. Chemotherapy and advanced imaging are associated with longer survival, whereas constrictive pericarditis and diffuse involvement indicate worse outcomes. Early recognition may reduce diagnostic delay. Findings should be interpreted with caution due to limitations of case-based data.

Indexed as

primary pericardial mesotheliomarare heart tumorsurvival

Identifiers

PMID42649897
PMCPMC13511537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.